The reverse split is a purely mechanical fix to avoid delisting and does not improve the company's financial health or pipeline prospects. Monitor the stock price closely on Aug 21 (first split-adjusted trading day) — failure to sustain a $1.00 close for 10 consecutive days by Sep 3 will trigger delisting, likely causing a catastrophic loss of liquidity and institutional ownership. The warrants (LIMNW) will also be affected by the proportional adjustment.
Price Chart
Executive Summary
Liminatus Pharma filed an 8-K confirming a 1-for-50 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price rule, after receiving multiple delisting notices and a final extension to September 3, 2026. The company has been transferred to the Nasdaq Capital Market but faces a hard deadline to demonstrate compliance or face delisting. This is a last-resort capital structure action that does not change the company's fundamentals or market cap, and the risk of eventual delisting remains high.
Key Facts
- Nasdaq notified the company of non-compliance with the MVLS Rule ($50M) and MVPHS Rule ($15M) on Nov 19, 2025, and with the Bid Price Rule ($1.00) on Jan 15, 2026.
- After a hearing, the Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective Aug 4, 2026, and granted an exception to demonstrate compliance with the $1.00 bid price rule by Sep 3, 2026.
- The Board approved a 1-for-50 reverse stock split, effective Aug 20, 2026, to boost the stock price above $1.00 and meet the continued listing standard.
- If the reverse split were implemented as of July 2, 2026, outstanding shares would have been reduced from 67,160,362 to approximately 1,343,208.
- The company has already failed to regain compliance with the Bid Price Rule and was not eligible for a second 180-day extension, making this a final attempt to avoid delisting.
Financial Impact
Reverse stock split at 1-for-50 ratio; no change to market cap or enterprise value. Outstanding shares would reduce from ~67.2M to ~1.34M based on July 2, 2026 count.
Risk Factors
- Failure to maintain a $1.00 closing bid price for 10 consecutive trading days by September 3, 2026, will result in delisting from Nasdaq.
- Reverse stock splits often lead to selling pressure as retail investors exit and the stock becomes more volatile at a lower float.
- The company has a market cap of only $9M and minimal institutional ownership (top holder Geode at $15K), indicating very limited support.
- No financial results or pipeline catalysts are provided in this filing — the business fundamentals remain opaque and likely weak.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-098335 |
| Document: tm2623497d1_ex3-1.htm | 0001104659-26-098335 |
| Document: tm2623497d1_ex99-1.htm | 0001104659-26-098335 |
| Document: 0001104659-26-098335-index-headers.html | 0001104659-26-098335 |
| Document: 0001104659-26-098335-index.html | 0001104659-26-098335 |
| Document: 0001104659-26-098335.txt | 0001104659-26-098335 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | 8-K | $0.1117 $0.0678 | ▲ +39.30% | ▲ +38.46% | $3.16 (−2729.01%) |
Jul 6, 2026 16w ago | 8-K | $0.1426 $0.1137 | ▲ +20.27% | ▲ +21.12% | $3.16 (−2115.99%) |
Jun 23, 2026 17w ago | S-1 | $0.1031 $0.1187 | ▲ +15.13% | ▲ +14.46% | $3.16 (+2964.99%) |
May 21, 2026 22w ago | Press Release | $0.1690 $0.1089 | ▲ +35.56% | ▲ +34.15% | $3.16 (−1769.82%) |
Mar 17, 2026 31w ago | Press Release | $0.2300 $0.1860 | ▼ −19.13% | ▼ −23.43% | $3.16 (+1273.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers